Biomol Ther.  2020 Mar;28(2):131-136. 10.4062/biomolther.2019.076.

Spinosin Attenuates Alzheimer’s Disease-Associated Synaptic Dysfunction via Regulation of Plasmin Activity

• Cai M
• Jung I
• Kwon H
• Cho E
• Jeon J
• Yun J
• Lee YC
• Kim DH
• Ryu JH

• KMID: 2507841
• DOI: http://doi.org/10.4062/biomolther.2019.076

Abstract

Hippocampal synaptic dysfunction is a hallmark of Alzheimer’s disease (AD). Many agents regulating hippocampal synaptic plasticity show an ameliorative effect on AD pathology, making them potential candidates for AD therapy. In the present study, we investigated spinosin as a regulating agent of synaptic plasticity in AD. Spinosin attenuated amyloid β (Aβ)-induced long-term potentiation (LTP) impairment, and improved plasmin activity and protein level in the hippocampi of 5XFAD mice, a transgenic AD mouse model. Moreover, the effect of spinosin on hippocampal LTP in 5XFAD mice was prevented by 6-aminocaproic acid, a plasmin inhibitor. These results suggest that spinosin improves synaptic function in the AD hippocampus by regulating plasmin activity.

Keyword

Spinosin; Alzheimer’s disease; Plasmin; LTP; 5XFAD